SniperFx

Archives

  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • September 2022
  • August 2022
  • January 2022
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019

Categories

  • Analysis
  • Bonds
  • Crypto
  • Forex
  • Forex Trading
  • Ideas
  • Investing
  • News
  • Stocks
  • World
Subscribe
SniperFx
SniperFx
  • Bonds
  • Crypto
  • Forex
    • Forex Trading
  • Ideas
  • Investing
  • Stocks
  • World

University of Queensland’s COVID vaccine technology finally moves to human trial phase after 2020 false start

  • admin
  • March 20, 2023

A human trial has been launched into the University of Queensland’s (UQ) second generation COVID vaccine, more than two years after the original technology was abandoned amid patients falsely testing positive to HIV.

Key points:

  • UQ researchers are working to create technology that can be used for multiple viruses
  • The original project was abandoned in 2020 and is now in its second generation
  • Researchers are seeking volunteers to participate in human trials

UQ scientists have re-engineered the molecular clamp technology and need 70 healthy volunteers aged 18 to 50 to test its effectiveness as a COVID vaccine compared to the approved Novavax shot.

Although the trial will assess the technology – dubbed Clamp2 — as a COVID vaccine, the researchers say if it’s successful, it’s more likely to be used to protect people during future pandemics and in jabs for existing viruses, such as respiratory syncytial virus (RSV).

Project leader Keith Chappell said the scientists were working on using the technology to create vaccines for “a range of viruses”.

“Our primary purpose is not to bring another COVID vaccine to market,” Associate Professor Chappell said.

“The vaccines that are out there are working extremely well and keeping a lot of people out of hospitals.

“This isn’t going to be the last time the world faces a pandemic and next time around, we want to … make sure there are doses available as quickly as possible and they’re safe, and they can protect Australians and people around the world.

“If we can show that this technology is safe and that it’s effective, the next time around we can ramp up extremely quickly and get vaccines to the people that need them in an emergency.”

Professor Chappell said he was “extremely confident” in the potential of Clamp2.

“I hope to one day save some lives and produce a vaccine that can make a difference,” he said.

What’s changed since last time?

The original clamp technology contained two fragments of a protein found in HIV, which acted like a chemical bulldog clip, holding together an engineered version of the spike protein found on the surface of SARS-CoV-2, the virus that causes COVID-19.

That worked by allowing the immune system to recognise – and attack – the spike protein, producing protective antibodies.

On its own, the SARS-CoV-2 spike protein is unstable. It needs to be locked into shape to ensure the vaccine produces a robust immune response.

But the molecular clamp used in the original UQ vaccine also resulted in people falsely testing positive to HIV, causing it to be dramatically abandoned.

Professor Chappell said the fragments of protein in HIV had been replaced by a “small amino acid sequence with similar properties” in Clamp2.

He could not reveal more details because of intellectual property protections.

“We had to go right back to square one to define something that had the right properties to be a molecular clamp,” Professor Chappell said.

“We also had to completely redefine how we manufactured this vaccine because we were using a specific purification methodology that would purify the original molecular clamp.

“Not only did we need to change the molecular clamp, we needed to change the purification methodology. We now have that working extremely well.”

The molecular virologist said vaccines using the UQ technology would have benefits over existing technology, once licensed by medicine regulators.

“They’ll be cheaper, they can get to regions of the world that are resource-limited and also have the stability to be able to be shipped around the world without having to be frozen at extremely low temperatures,” Professor Chappell said.

“The biggest benefit in terms of pandemic preparedness is that it can be rapidly scaled up into millions and millions of doses.”

Researchers seeking trial participants

Professor Chappell said volunteers wanted for Clamp2’s first human trial need to have received a COVID vaccine, but not in the past three months.

They also cannot have contracted SARS-CoV-2 in the past three months.

“There are no overnight stays required and participants will be reimbursed for their time,” he said.

Want more local stories?

We’ve got an ABC News homepage for you. Adjust your settings for the right mix of local and national news.

The Coalition for Epidemic Preparedness Innovation (CEPI) is providing up to $8.5 million to support further development of the UQ technology for use in the global response to future disease outbreaks.

Nucleus Network will conduct the trial in Brisbane. Half the participants will be given one dose of the UQ vaccine and the rest will receive Novavax’s COVID shot.

They will be monitored for six months.

admin

Previous Article

Liam Neeson Reveals Rejecting James Bond’s Role Because Of His Then Girlfriend

  • admin
  • March 20, 2023
View Post
Next Article

Beware of fake Arbitrum Airdrops, community warns

  • admin
  • March 20, 2023
View Post
You May Also Like
View Post
  • News

COVID-19 tracker Tokyo reports 1,357 new cases

  • admin
  • April 5, 2023
View Post
  • News

About 4 million Queenslanders contracted COVID-19 at least once in 2022, Chief Health Officer says

  • admin
  • April 4, 2023
View Post
  • News

Long COVID exercise trials proposed by NIH raise alarm

  • admin
  • April 1, 2023
View Post
  • News

300 Covid Cases In 24 Hours In Delhi For The First Time Since September

  • admin
  • March 30, 2023
View Post
  • News

Game-Changer Nasal Spray A Universal Shield Against All COVID-19 Variants

  • admin
  • March 29, 2023
View Post
  • News

Trans-Atlantic container rates still double pre-COVID levels

  • admin
  • March 28, 2023
View Post
  • News

Shanghai expat exodus shows ‘zero-COVID’s’ enduring scars

  • admin
  • March 27, 2023
View Post
  • News

LA County Health Officials Say COVID Rules Remain in Effect at California Worksites

  • admin
  • March 26, 2023

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories
  • Analysis (33)
  • Bonds (70)
  • Crypto (90)
  • Forex (106)
  • Forex Trading (64)
  • Ideas (57)
  • Investing (61)
  • News (121)
  • Stocks (113)
  • World (200)
Recent Posts
  • ISS backs Toyota shareholder proposal on climate disclosure
  • Gold Prices at Risk of Deeper Correction on Surging Real Yields, USD Strength
  • US Dollar Weekly Outlook Will US Debt Ceiling Deal and Jobs Report Boost DXY Further
  • BTC’s Network Activity Has Started Recovering From Its May Lows
  • USDCHF double three Elliott Wave advance and next blue box area
SniperFx
  • Home
  • About Us
  • Contact
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
Forex & Crypto Updates

Input your search keywords and press Enter.